Cite
HARVARD Citation
Di Giacomo, A. et al. (n.d.). 192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. Immuno-oncology technology. p. . [Online].